Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Carcinoma, Non-Small-Cell Lung 8Neoplasms 2Squamous Non-small Cell Lung Cancer 1Squamous Non Small Cell Lung Cancer 1Solid Tumors 1Solid Tumor, Adult 1Neoplasm Metastasis 1Colorectal Neoplasms 1Carcinoma 1Breast Neoplasms 1

Interventions

Gemcitabine 9Paclitaxel 8Carboplatin 7atezolizumab 6Sunitinib 5navitoclax 4Topotecan 4Irinotecan 4Docetaxel 4Bevacizumab 4pazopanib 3liposomal doxorubicin 3cobimetinib 3Nivolumab 3Erlotinib Hydrochloride 3zolbetuximab 2tumor necrosis factor-alpha, CNGRC fusion protein, human 2temsirolimus 2selicrelumab 2plocabulin 2envafolimab 2darinaparsin 2brigimadlin 2adavosertib 2Tablets 2Sorafenib 2Rifampin 2RG7388 2Panitumumab 2NVP-BKM120 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Solid Tumors × necitumumab × Clear all
NCT01624467 2016-07-25

A Study of Necitumumab Monotherapy and the QT/QTc Interval in Patient With Advanced Solid Tumors

Eli Lilly and Company

Phase 2 Completed
75 enrolled 12 charts
Other solid neoplasm

Solid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡